Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...